Alpelisib (BYL719)

Alpelisib (BYL719)

Cat. No.: DIA-0231294

Size: 50 mg Size: 500 mg Size: Customer Size
Product Information
CAS No. 1217486-61-7
Formula C19H22F3N5O2S
Molecular Weight 441.47
SMILES CC1=C(SC(=N1)NC(=O)N2CCCC2C(N)=O)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
Target PI3Kα
Product Description Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.
Format & Storage
Purity > 99%
Shipping Shipped on dry ice.
Storage Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month
Solubility Overview Soluble in DMSO
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
logo

Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.

Quick Links
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.
Top